Tesamorelin peptide vs sermorelin: how they actually differ

Last updated 2026-07-24

What is the difference between tesamorelin and sermorelin?

Both are growth-hormone-releasing hormone (GHRH) analogs. They work the same way: they bind GHRH receptors on the pituitary and tell it to release its own growth hormone, rather than injecting growth hormone directly. That's the whole family resemblance. The difference is in the molecule and the paperwork. Sermorelin is a 29-amino-acid fragment of natural GHRH (the first 29 residues, which is the smallest piece that still activates the receptor). Tesamorelin is a modified, stabilized 44-amino-acid analog with an extra trans-3-hexenoic acid group tacked onto the front end, which slows its breakdown in the blood. That structural tweak matters clinically. Tesamorelin resists enzymatic degradation better than unmodified GHRH fragments, which is part of why it made it through large trials for a specific condition (HIV-associated lipodystrophy) and got FDA approval under the brand Egrifta. Sermorelin never went through that scale of testing for any current indication; its old branded version, Geref, was approved decades ago for diagnostic and pediatric growth hormone deficiency use and was discontinued by the manufacturer, not pulled for a safety problem ^[1]. Today, if you're getting either peptide, you're almost certainly getting sermorelin from a compounding pharmacy rather than a manufactured, FDA-approved product, because Geref isn't on the market. Tesamorelin as Egrifta is still an approved drug you can find in the FDA's own database ^[2].

Is tesamorelin FDA-approved and is sermorelin?

Tesamorelin (Egrifta, Egrifta SV) is FDA-approved, but for one narrow use: reduction of excess abdominal fat in HIV patients with lipodystrophy. You can look it up directly in Drugs@FDA, the agency's own approved-drug database ^[2]. That's it. It is not approved for anti-aging, muscle building, athletic performance, or general growth hormone deficiency in adults without HIV. Sermorelin has no currently-approved branded product in the US. Its old approved version, Geref, was FDA-cleared for diagnosing growth hormone deficiency and for treating pediatric GHD, and the manufacturer discontinued it for commercial reasons rather than because of a safety finding ^[1]. Since Geref left the market, sermorelin has lived on almost entirely as a compounded product. Compounded sermorelin sits in a specific regulatory lane. Under 21 U.S.C. 353a, pharmacies can compound drugs from bulk substances under certain conditions, and the FDA maintains lists of what's allowed for 503A compounding pharmacies and 503B outsourcing facilities ^[3][4]. Sermorelin's regulatory status has moved around over the years as FDA reviewed nominations to these bulk drug lists; the current lists are the FDA's authoritative reference point, not marketing claims from a seller ^[5]. If you're comparing options, this difference (one approved drug for a specific condition, one compounded peptide with a discontinued approved history) is the single most important fact to understand before anything else.

Tesamorelin vs sermorelin: side-by-side comparison

How do dosing schedules for tesamorelin and sermorelin compare?

Egrifta's FDA-approved dosing is 2 mg by subcutaneous injection once daily, per the approved labeling reflected in Drugs@FDA ^[2]. That's a fixed, studied dose behind a specific approved product. Sermorelin dosing is far less standardized because it isn't a single approved drug anymore. Compounding pharmacies and prescribers typically dose it in the range of roughly 0.2 mg to 0.3 mg subcutaneously at bedtime, mimicking the body's natural nighttime growth hormone pulse, but exact protocols vary by prescriber and compounder because there's no single FDA label to anchor the number. This is a real limitation: without one approved product, dosing consistency depends on the individual pharmacy and prescriber, not a uniform standard. Both peptides are typically injected before bed, since that's when natural GH release peaks and GHRH analogs work with, not against, that rhythm. Neither is a once-and-done treatment. Tesamorelin trials that led to Egrifta approval used continuous daily dosing over months; sermorelin protocols for adults also run over months, though the supporting literature here is thinner and older ^[7].

Which one has more clinical evidence behind it?

Tesamorelin has the harder, more recent evidence for its approved use. It went through the randomized trial process required for FDA approval, specifically for reducing visceral fat in HIV lipodystrophy, and that data is what's in its label at Drugs@FDA ^[2]. Sermorelin's strongest evidence is older and mostly in a different population. A 1999 review in BioDrugs covered its use in diagnosing and treating idiopathic growth hormone deficiency in children ^[7], which is a different clinical question than "does this help an adult with age-related GH decline." A 2006 paper in Clinical Interventions in Aging asked whether sermorelin might be a better approach to managing adult-onset growth hormone insufficiency, but this is a narrower, more cautious literature than a large approval-grade trial program ^[1]. More broadly, growth hormone secretagogues (the class both peptides belong to) have been studied in hypogonadal men: one study found that GH secretagogue treatment raised serum IGF-1 levels in this population , and a related review in Translational Andrology and Urology looked at their role in body composition management in hypogonadal males ^[3]. These are real findings worth knowing, but they're about a specific population (hypogonadal men) and a specific marker (IGF-1), not a blanket claim that either peptide reverses aging or builds muscle in healthy adults. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews looked at therapeutic peptides broadly in orthopaedic applications, and a 2026 Sports Medicine paper reviewed safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance ^[8][9]. Both signal that peptide research in this space is active and still developing, which is a fair way to describe where the science stands: moving, not settled.

Does tesamorelin or sermorelin work better for fat loss?

Tesamorelin is the one with an approved indication tied directly to fat: reducing excess abdominal fat in HIV-associated lipodystrophy, per its FDA approval ^[2]. That's a specific, studied outcome in a specific population, not a general "burns belly fat" claim for the public. Sermorelin doesn't have an approved fat-loss indication at all. Some of the secretagogue literature touches on body composition in hypogonadal men ^[3], and raised IGF-1 has been observed with GH secretagogue treatment in that population , but IGF-1 going up is not the same claim as measurable fat loss in a general adult population. If a clinic markets sermorelin primarily as a fat-loss peptide for otherwise healthy adults, that's marketing outrunning the evidence, not something backed by an approval or a large trial program. If visceral fat reduction specifically is the goal and HIV-associated lipodystrophy is the actual diagnosis, tesamorelin is the peptide with regulatory and trial support behind it. Outside that specific diagnosis, neither peptide has approval-grade fat-loss evidence, and you should treat any such claim as off-label speculation, not established fact.

Are tesamorelin and sermorelin equally safe?

Both are generally considered to have mild, similar side effect profiles compared to injecting growth hormone itself, since they stimulate your own pituitary rather than adding external hormone. Common reactions reported for GHRH analogs as a class include injection site redness, headache, flushing, and occasional nausea. Because tesamorelin went through FDA trials for its approved indication, its label carries more codified safety information specific to that population (HIV patients) ^[2]. Sermorelin's modern safety picture leans more on its older approval history as Geref plus newer, smaller studies, since there's no current large-scale approved trial program behind it ^[1][7]. A broader safety flag worth knowing: growth hormone axis manipulation over long periods, whether through GH itself or GHRH analogs, isn't risk-free. A 2026 case report in Frontiers in Surgery described anterior cervical osteophyte-related dysphagia in a long-term growth hormone user , a reminder that chronic GH pathway stimulation can have structural consequences worth monitoring, even if that specific case involved GH rather than a GHRH analog. Sermorelin has also been looked at in an unusual context: a 2021 paper in Annals of Translational Medicine explored it as a potentially effective drug for patients with recurrent glioma ^[10], which is interesting research but not a safety endorsement for general use, and definitely not a reason to self-prescribe. For a full rundown of what long-term sermorelin use looks like in practice, see sermorelin long-term side effects.

Can you combine tesamorelin and sermorelin?

Some prescribers do combine GHRH analogs with GHRP-type secretagogues, or occasionally discuss tesamorelin and sermorelin together, on the theory that hitting the GHRH pathway from more than one direction might add benefit. The honest answer is that rigorous head-to-head trial data on stacking these two specific peptides is thin to nonexistent in the public literature reviewed here. If you're considering this, the right place to get a straight answer is a conversation with a prescriber who can look at your labs, your goals, and your actual diagnosis, not a peptide seller's dosing chart. We cover the stacking question in more depth in can you stack tesamorelin and sermorelin. One general caution applies to any peptide combination: more isn't automatically better, and stacking increases the number of things that can go wrong (injection site issues, unclear dosing math, interactions) without a matching increase in known benefit.

How is sermorelin different from HGH itself?

This is the question most people are actually trying to answer, so it deserves a direct treatment. HGH (human growth hormone, usually somatropin) is the hormone itself, injected directly. Sermorelin is not HGH; it's a signal that tells your own pituitary to make and release more of its own GH. That difference has real consequences. Direct HGH injection bypasses your body's feedback loops, which is part of why it carries a more serious side effect profile at supraphysiologic doses (fluid retention, joint pain, insulin resistance, and, in the case report noted above, structural changes with long-term use ). Sermorelin works within your pituitary's own ceiling. If your pituitary can't respond, sermorelin won't produce much of an effect, which is a real limitation, not a footnote. This is also honestly the weaker case for sermorelin: it's a gentler, more modest intervention, and if you need a large, fast, guaranteed rise in GH or IGF-1, sermorelin is not going to get you there the way direct HGH will. Sermorelin's history as the FDA-approved product Geref (used for GHD diagnosis and pediatric treatment) gives it a real regulatory paper trail that most peptides being sold today simply don't have, even though that branded product is discontinued now ^[1][7]. That history is worth something when you're deciding who to trust, even if it doesn't mean sermorelin is currently approved for adult use. For a broader look at how sermorelin stacks up against direct HGH across cost, effect size, and monitoring, see the main sermorelin overview.

Why is sermorelin harder to find as a branded product than tesamorelin?

Simple commercial history. Geref, the branded sermorelin acetate product, was FDA-approved and then discontinued by its manufacturer; discontinuation for business reasons is different from a safety withdrawal, and it's worth being precise about that distinction because it changes how you should read the peptide's risk profile ^[1]. Tesamorelin as Egrifta remains an active, marketed, FDA-approved product today, which you can verify directly in Drugs@FDA ^[2]. That's why a tesamorelin prescription usually means an approved manufactured drug, while a sermorelin prescription usually means a compounded product made under 503A or 503B rules ^[3][4]. Compounded status isn't automatically bad, pharmacies compound plenty of legitimate, needed medications, but it does mean quality and consistency depend heavily on which pharmacy is doing the compounding and how they source their raw material. That's a sourcing question, not a molecule question, and it's worth reading separately from the science. See best place to buy sermorelin and sermorelin reviews if that's your next question.

How is tesamorelin or sermorelin detected in drug testing?

This matters if you're an athlete or in any tested profession, since GHRH analogs are prohibited in most competitive sport. Detection science here has moved fast in the last decade. Researchers have developed antibody-free, ultrafiltration-based assays that can detect GHRH-class peptides in urine at low picogram-per-milliliter concentrations using high-resolution mass spectrometry ^[11], and separate teams have built cationic exchange solid-phase extraction methods combined with triple quadrupole UHPLC-MS/MS specifically to catch GHRHs in urine ^[5]. Other labs have used capillary electrophoresis with large-volume sample stacking to separate enantiomeric GHRH analogs ^[7], and immunoaffinity purification combined with LC-HRMS/MS has been used to qualitatively identify GHRH-class peptides directly in human plasma . A 2021 review in Drug Testing and Analysis specifically tracked advances in detecting synthetic GHRH analogs like tesamorelin and sermorelin ^[6], and a 2026 paper looked at nano-LC coupled to quadrupole/orbitrap mass spectrometry for the same purpose in urine . The practical takeaway: these peptides are not "undetectable," and testing labs have specifically built methods around this exact drug class. A 2026 critical review in The Journal of Sports Medicine and Physical Fitness covered the broader rise of peptide and peptide-analog drugs in recreational and professional sport ^[12], which is worth reading if performance context is part of why you're comparing these two peptides in the first place.

What does tesamorelin or sermorelin cost, and is either covered by insurance?

Tesamorelin as Egrifta is expensive as a branded specialty drug; list prices for branded GHRH analogs commonly run into four figures per month before insurance, though your actual cost depends heavily on insurance coverage, since it's approved specifically for HIV-associated lipodystrophy and insurers generally require that diagnosis to cover it. Compounded sermorelin is typically cheaper per month than a branded specialty drug like Egrifta, but exact pricing varies widely by pharmacy, dose, and region, and because it's a compounded product used off-label, insurance essentially never covers it. You're paying out of pocket, which is worth planning for before you start. Neither cost comparison is a reason on its own to pick one peptide over the other; the diagnosis and the actual clinical goal should drive that decision, with cost as a practical follow-up question you work through with your prescriber and pharmacy.

Frequently asked questions

Is tesamorelin stronger than sermorelin?

Not exactly stronger, but more stable in the body due to its structural modification, which helps it resist enzymatic breakdown. Tesamorelin also has FDA approval and trial data behind one specific use (HIV lipodystrophy), while sermorelin's approved history (as Geref) has ended. "Stronger" depends on what outcome you're measuring and for whom.

Can I switch from sermorelin to tesamorelin or vice versa?

That's a decision for your prescriber, not something to do on your own. The two peptides have different molecular structures, different approved uses, and different dosing histories. A prescriber who knows your diagnosis, labs, and goals is the right person to decide whether switching makes sense.

Why was Geref (branded sermorelin) discontinued?

Geref was discontinued by its manufacturer for business reasons, not because of a safety finding pulled by the FDA. It's an important distinction: the molecule wasn't found dangerous, the branded product simply left the market, which is why sermorelin today is almost always a compounded product instead.

Is sermorelin legal to buy in the US?

Sermorelin can be legally prescribed and compounded under the rules governing 503A and 503B pharmacies, per 21 U.S.C. 353a and the FDA's bulk drug substance lists. Legality depends on getting it through a legitimate prescriber and compounding pharmacy, not from unregulated online sellers.

Does sermorelin do the same thing as HGH?

No. HGH is the hormone itself, injected directly. Sermorelin signals your own pituitary to release more of its own GH, working within your body's natural feedback limits. If your pituitary function is significantly impaired, sermorelin will have a limited effect where direct HGH would not.

What is tesamorelin actually approved to treat?

Tesamorelin (brand name Egrifta/Egrifta SV) is FDA-approved specifically to reduce excess abdominal fat in people with HIV-associated lipodystrophy, per its listing in the FDA's Drugs@FDA database. It is not approved for general fat loss, anti-aging, or muscle building in the broader population.

Are tesamorelin and sermorelin banned in sports?

GHRH-class peptides, including tesamorelin and sermorelin, are prohibited substances in most competitive sport testing programs. Detection methods using high-resolution mass spectrometry and immunoaffinity purification have specifically been developed to catch this drug class in urine and plasma samples.

How long does it take to see effects from tesamorelin or sermorelin?

Tesamorelin's approved trials for lipodystrophy involved months of continuous daily dosing before measurable fat reduction was documented. Sermorelin protocols in the older pediatric and adult literature similarly run over months, not weeks. Neither peptide is a fast-acting treatment; both require sustained use to judge.

Is sermorelin covered by insurance?

Generally, no. Sermorelin is used off-label today as a compounded product since its branded approved version (Geref) was discontinued, and off-label compounded peptides are typically not covered by insurance. You should expect to pay out of pocket and confirm current pricing with your prescribing clinic and pharmacy.

What are the side effects of tesamorelin compared to sermorelin?

Both commonly cause mild injection site reactions, headache, and occasional flushing. Tesamorelin's FDA label reflects safety data collected specifically in HIV patients from its approval trials. Sermorelin's safety picture rests more on older approval history and smaller studies, since it lacks a current large trial program.

Can tesamorelin and sermorelin be stacked together?

Some prescribers discuss combining GHRH-pathway peptides, but rigorous published trial data specifically comparing or combining tesamorelin and sermorelin is limited. This is a decision to make with a prescriber who can review your labs and goals, not something to attempt from a generic dosing guide.

Which peptide has better research support, tesamorelin or sermorelin?

Tesamorelin has stronger, more recent trial support tied to its one FDA-approved indication. Sermorelin's evidence base is older, centered on pediatric growth hormone deficiency, with smaller adult studies since. Neither has strong evidence for anti-aging or athletic performance claims in healthy adults.

Sources

1. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Reviews therapeutic peptides in orthopaedic applications, challenges, and future directions.
2. Sports Medicine (Auckland), 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance.
3. Drug Testing and Analysis, 2021 (PMID 34665524): Covers advances in detecting synthetic GHRH analogs including tesamorelin and sermorelin.
4. Translational Andrology and Urology, 2020 (PMID 32257855): Reviews the role of growth hormone secretagogues in body composition management in hypogonadal males.
5. FDA, bulk drug substances used in compounding under section 503A: Explains the FDA framework governing which bulk substances, including sermorelin, pharmacies may use under 503A compounding.
6. Clinical Interventions in Aging, 2006 (PMID 18046908): Discusses sermorelin's history including its prior branded approval (Geref) and its discontinuation, and its potential role in adult-onset GH insufficiency.
7. FDA, bulk drug substances nominated for use in compounding (current list): Lists bulk drug substances, including sermorelin, nominated and reviewed for compounding use.
8. BioDrugs, 1999 (PMID 18031173): Reviews sermorelin's use in diagnosing and treating idiopathic growth hormone deficiency in children.
9. Annals of Translational Medicine, 2021 (PMID 33842627): Explores sermorelin as a potentially effective drug for patients with recurrent glioma.
10. Drugs@FDA, FDA-approved drug products database: Confirms tesamorelin (Egrifta/Egrifta SV) is FDA-approved for reduction of excess abdominal fat in HIV-associated lipodystrophy, with defined dosing.
11. Journal of Pharmaceutical and Biomedical Analysis, 2022 (PMID 35298973): Describes an antibody-free ultrafiltration assay detecting GHRH-class peptides in urine at low pg/mL levels.
12. The Journal of Sports Medicine and Physical Fitness, 2026 (PMID 41880199): Critically reviews the use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding.
13. American Journal of Men's Health, 2017 (PMID 28830317): Found growth hormone secretagogue treatment raises serum IGF-1 levels in hypogonadal men.
14. Analytical and Bioanalytical Chemistry, 2016 (PMID 26879649): Describes immunoaffinity purification and LC-HRMS/MS methods for qualitative identification of GHRHs in human plasma.
15. Frontiers in Surgery, 2026 (PMID 42465868): Case report of anterior cervical osteophyte-related dysphagia in a long-term growth hormone user.
16. 21 U.S.C. 353a, pharmacy compounding (Cornell Law): Establishes the legal conditions under which pharmacies may compound drugs like sermorelin from bulk substances.